These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
338 related articles for article (PubMed ID: 31554423)
1. Comparison of the Effects of Ticagrelor and Clopidogrel on Microvascular Dysfunction in Patients With Acute Coronary Syndrome Using Invasive Physiologic Indices. Park K; Cho YR; Park JS; Park TH; Kim MH; Kim YD Circ Cardiovasc Interv; 2019 Oct; 12(10):e008105. PubMed ID: 31554423 [TBL] [Abstract][Full Text] [Related]
2. Comparison between ticagrelor and clopidogrel on myocardial blood flow in patients with acute coronary syndrome, using 13 N-ammonia positron emission tomography. Jeong YJ; Park K; Kim YD Am Heart J; 2020 Apr; 222():121-130. PubMed ID: 32028138 [TBL] [Abstract][Full Text] [Related]
3. Design and Rationale for comParison Between ticagreLor and clopidogrEl on mIcrocirculation in Patients with Acute cOronary Syndrome Undergoing Percutaneous Coronary Intervention (PLEIO) Trial. Park K; Cho YR; Park JS; Park TH; Kim MH; Kim YD J Cardiovasc Transl Res; 2018 Feb; 11(1):42-49. PubMed ID: 29344840 [TBL] [Abstract][Full Text] [Related]
4. Impact of Ticagrelor Versus Clopidogrel on Coronary Microvascular Function After Non-ST-Segment-Elevation Acute Coronary Syndrome. Xu J; Lo S; Mussap CJ; French JK; Rajaratnam R; Kadappu K; Premawardhana U; Nguyen P; Juergens CP; Leung DY Circ Cardiovasc Interv; 2022 Apr; 15(4):e011419. PubMed ID: 35369712 [TBL] [Abstract][Full Text] [Related]
5. Comparing the effect of clopidogrel versus ticagrelor on coronary microvascular dysfunction in acute coronary syndrome patients (TIME trial): study protocol for a randomized controlled trial. Park SD; Baek YS; Woo SI; Kim SH; Shin SH; Kim DH; Kwan J; Park KS Trials; 2014 May; 15():151. PubMed ID: 24885437 [TBL] [Abstract][Full Text] [Related]
6. Clinically Significant Bleeding With Ticagrelor Versus Clopidogrel in Korean Patients With Acute Coronary Syndromes Intended for Invasive Management: A Randomized Clinical Trial. Park DW; Kwon O; Jang JS; Yun SC; Park H; Kang DY; Ahn JM; Lee PH; Lee SW; Park SW; Choi SW; Lee SG; Yoon HJ; Ahn T; Kim MH; Nah DY; Lee SY; Chae JK; Park SJ; Circulation; 2019 Dec; 140(23):1865-1877. PubMed ID: 31553203 [TBL] [Abstract][Full Text] [Related]
7. Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial. Berger JS; Abramson BL; Lopes RD; Heizer G; Rockhold FW; Baumgartner I; Fowkes FGR; Held P; Katona BG; Norgren L; Jones WS; Millegård M; Blomster J; Reist C; Hiatt WR; Patel MR; Mahaffey KW Vasc Med; 2018 Dec; 23(6):523-530. PubMed ID: 29992857 [TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes after ticagrelor and clopidogrel in Chinese post-stented patients. Sun Y; Li C; Zhang L; Yu T; Ye H; Yu B; Tao M; Jiang J; Yan J; Wang Y; Zeng H; Shen X; Wang DW Atherosclerosis; 2019 Nov; 290():52-58. PubMed ID: 31568962 [TBL] [Abstract][Full Text] [Related]
9. Ticagrelor Does Not Improve Endothelial Dysfunction in Stable Survivors of Acute Coronary Syndrome. Lim S; Choo EH; Kim CJ; Choi IJ; Lee KY; Hwang BH; Lee JM; Chung WS; Chang K J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):442-449. PubMed ID: 31035775 [TBL] [Abstract][Full Text] [Related]
10. Ticagrelor Versus Clopidogrel in Patients with Late or Very Late Stent Thrombosis. Zhou J; Tan Y; Liu C; Zhou P; Sheng Z; Li J; Chen R; Zhao H; Song L; Yan H Cardiovasc Drugs Ther; 2020 Oct; 34(5):677-684. PubMed ID: 32572652 [TBL] [Abstract][Full Text] [Related]
11. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial. Gimbel M; Qaderdan K; Willemsen L; Hermanides R; Bergmeijer T; de Vrey E; Heestermans T; Tjon Joe Gin M; Waalewijn R; Hofma S; den Hartog F; Jukema W; von Birgelen C; Voskuil M; Kelder J; Deneer V; Ten Berg J Lancet; 2020 Apr; 395(10233):1374-1381. PubMed ID: 32334703 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of Microvascular Injury in Revascularized Patients With ST-Segment-Elevation Myocardial Infarction Treated With Ticagrelor Versus Prasugrel. van Leeuwen MAH; van der Hoeven NW; Janssens GN; Everaars H; Nap A; Lemkes JS; de Waard GA; van de Ven PM; van Rossum AC; Ten Cate TJF; Piek JJ; von Birgelen C; Escaned J; Valgimigli M; Diletti R; Riksen NP; van Mieghem NM; Nijveldt R; van Royen N Circulation; 2019 Jan; 139(5):636-646. PubMed ID: 30586720 [TBL] [Abstract][Full Text] [Related]
13. Different Microcirculation Response Between Culprit and Non-Culprit Vessels in Patients With Acute Coronary Syndrome. Jo YS; Moon H; Park K J Am Heart Assoc; 2020 May; 9(10):e015507. PubMed ID: 32410526 [TBL] [Abstract][Full Text] [Related]
15. Early Effects of Ticagrelor Versus Clopidogrel on Peripheral Endothelial Function After Non-ST-Elevation Acute Coronary Syndrome and Assessment of Its Relationship With Coronary Microvascular Function. Xu J; Lo S; Mussap CJ; French JK; Rajaratnam R; Kadappu K; Premawardhana U; Nguyen P; Juergens CP; Leung DY Am J Cardiol; 2023 Aug; 201():16-24. PubMed ID: 37348152 [TBL] [Abstract][Full Text] [Related]
16. Beneficial effect of ticagrelor on microvascular perfusion in patients with ST-segment elevation myocardial infarction undergoing a primary percutaneous coronary intervention. Wang X; Li X; Wu H; Li R; Liu H; Wang L; Bai S; Zhang L; Chen T; Liu J; Li Q; Du R Coron Artery Dis; 2019 Aug; 30(5):317-322. PubMed ID: 30614823 [TBL] [Abstract][Full Text] [Related]
17. Diabetes and CYP2C19 Polymorphism Synergistically Impair the Antiplatelet Activity of Clopidogrel Compared With Ticagrelor in Percutaneous Coronary Intervention-treated Acute Coronary Syndrome Patients. Mohareb MW; AbdElghany M; Zaki HF; El-Abhar HS J Cardiovasc Pharmacol; 2020 Oct; 76(4):478-488. PubMed ID: 32675750 [TBL] [Abstract][Full Text] [Related]
18. Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk. Baber U; Leisman DE; Cohen DJ; Gibson CM; Henry TD; Dangas G; Moliterno D; Kini A; Krucoff M; Colombo A; Chieffo A; Sartori S; Witzenbichler B; Steg PG; Pocock SJ; Mehran R Circ Cardiovasc Qual Outcomes; 2019 Jan; 12(1):e004945. PubMed ID: 30606052 [TBL] [Abstract][Full Text] [Related]
19. Ticagrelor enhances the cardioprotective effects of ischemic preconditioning in stable patients undergoing percutaneous coronary intervention: the TAPER-S randomized study. D'Amario D; Galli M; Restivo A; Canonico F; Vergallo R; Migliaro S; Trani C; Burzotta F; Aurigemma C; Laborante R; Romagnoli E; Francese F; Ceccarelli I; Borovac JA; Angiolillo DJ; Tavazzi B; Leone AM; Crea F; Patti G; Porto I Eur Heart J Cardiovasc Pharmacother; 2024 May; 10(3):190-200. PubMed ID: 38006237 [TBL] [Abstract][Full Text] [Related]
20. Risk of Major Bleeding With Potent Antiplatelet Agents After an Acute Coronary Event: A Comparison of Ticagrelor and Clopidogrel in 5116 Consecutive Patients in Clinical Practice. Mullen L; Meah MN; Elamin A; Aggarwal S; Shahzad A; Shaw M; Hasara J; Rashid M; Fisher M; Ali T; Patel B; Ding WY; Grainger R; Heseltine T; Kirmani BH; Obeidat M; Kasolo Y; Thatchil J; Khand A J Am Heart Assoc; 2021 Apr; 10(8):e019467. PubMed ID: 33834845 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]